Roxithromycin antagonizes catagen induction in human hf

bornthisway

Established Member
Reaction score
9
Again..:

Roxithromycin antagonizes catagen induction in murine and human hair follicles: implication of topical roxithromycin as hair restoration reagent

Arch Dermatol Res. 2008 Sep 27
Ito T, Fukamizu H, Ito N, Seo N, Yagi H, Takigawa M, Hashizume H.

Department of Dermatology, Hamamatsu University School of Medicine, 1-20-1 Handayama Higashi-ku, Hamamatsu, 431-3192, Japan

Roxithromycin (RXM) is a 14-member macrolide antibiotics, with a variety of bioregulatory functions including anti-apoptotic activity to keratinocytes. Therefore, RXM has been used for many kinds of skin diseases. In this study, human and murine hair follicles were treated with RXM in order to find the possibility to cure hair loss disease such as androgenetic alopecia (Androgenetic Alopecia). In Androgenetic Alopecia, dihydrotestosterone signals apoptosis in dermal papilla cells in susceptible individuals, resting in premature termination of anagen and early entry into catagen. Therefore, anti-apoptotitic drug has a possibility of new candidate for Androgenetic Alopecia. This study revealed RXM antagonized the in vitro inhibitory effect of IFN-gamma on proliferation of keratinocytes and induction of apoptosis in murine and human hair bulb. RXM increases hair elongation and inhibits catagen-like changes induced in vitro with IFN-gamma in murine and human hair follicles. Furthermore, topical 5% RXM solution effectively restores hair growth in about half of individuals with Androgenetic Alopecia without any local and systemic adverse effects. Therefore, RXM is new candidate as a hair restoration drug for Androgenetic Alopecia.
 

michael barry

Senior Member
Reaction score
12
Roxythromicyn has now been tested for androgenic alopecia in people in Japan. The results were hardly inspiring. Only a little more than half (58%), saw any improvement at all



http://www.turboupload.com/files/gen/5Z ... lltext.pdf








Only 7 out of 13 patients improved over baseline at 24 weeks (six months) . Thats merely 58% according to the study.


Thats hardly a ringing endorsement. Can Roxythromicyn be helpful? Sure........... but a cure for baldness?.......Finasteride peforms better than this in trials and so does minoxidil.



Of the people who saw improvement, , 34% saw 'improvement', and 17% saw slight improvementonly 7% were described as seeing great improvement


Ketoconazole lotion had better results than this, finasteride outdoes this, minoxidil outdoes this......................I think it can be an "aid" but its not something to base a regimine around.




BTW----We dont know what it is that the immune system attacks in Androgenetic Alopecia, we simply know the first inflammation occurs at the infidula, but we dont know why yet
 

larry27

New Member
Reaction score
0
dont you think the keto estudy is something... imcomplete?

there are not much people in this estudy
 

michael barry

Senior Member
Reaction score
12
There are three Nizoral studies that confirm that it regrows hair.


There is one ketoconazole cream study that has some astonishing regrowth photos.



Hair counts, hair weights increased in each of the four studies, and sebum was reduced in all studies. Thats pretty damned effective. Here are three of the studies:


Nizoral 1% Study Shows Benefits for Androgenetic Alopecia

March 04, 2001 - American Academy of Dermatology Meeting - Washington DC - Scientists working for McNeil, makers of Nizoral anti-dandruff shampoo, presented the findings of a study done on 1% Nizoral shampoo which has good news for hair loss sufferers. It has long been known that 2% prescription Nizoral has beneficial effects on Androgenic Alopecia (male pattern baldness). It however has been unclear whether the same benefits can be obtained by using the non-prescription 1% version.
In the study presented (see below), one hundred male volunteers with mild to moderate dandruff and somewhat oily scalp, were using, in a double-blind fashion, either a 1% Nizoral shampoo or a 1% zinc pyrithione shampoo, 2-3 times a week for 6 months.

Analysis of the different parameters set up in the study shows that the hair diameter gradually increased with Nizoral use (+8.46%) over a 6 month period, whereas the diameter showed a trend to decrease with zinc pyrithione use over the same period (-2.28%). The sebum excretion rate was reduced with Nizoral (-6.54%) while it increased with zinc pyrithione (+8.2%) over the same period of time. The number of hair shed over a 24-hour period was reduced by 16.46% with Nizoral and 6.02% with zinc pyrithione after 6 months. Finally, the percentage hairs in anagen phase increased by 6.4% and 8.4% respectively during the study time.

The results are similar to a previous study done on 2% prescription strength Nizoral where it was shown that use of 2% Nizoral yielded a 7% average increase in hair shaft diameter similar to what was achieved by the control group using 2% Minoxidil and a non-medicated shampoo.

So for any hair loss sufferer, this research clearly indicates that using 1% or 2% Nizoral 2-3 times per week, will have positive effects on hair growth as well as controlling dandruff. It is still unclear at this time whether it's the anti-fungal properties or the anti-androgenic properties of Ketokonazole (active ingredient in Nizoral) thats responsible for the hair thickening effects, however because of the decrease in sebum rates as well, it is the authors opinion that the results are due to the anti-androgenic properties of Ketokonazole
.




Nizoral 1% Study
The effects of chronic use of 1% ketoconazole or a 1% zinc pyrithione shampoo on the general health of hair and scalp.

G. Piérard 1and G. Cauwenbergh2
1. Dept Dermatopathology, University of Liège, Belgium; 2. Skin research Center, Johnson &Johnson , Skillman, N.J., USA

Hundred male volunteers with mild to moderate dandruff and somewhat oily scalp, have used, in a double-blind fashion, a 1% ketoconazole shampoo or a 1% zinc pyrithione shampoo. The test shampoos were applied 2 to 3 times weekly for a total period of 6 months. Several parameters that affect the general health of hair and scalp were assessed at start, and after 1, 3 and 6 months. These parameters included the percent of hairs in anagen phase, the diameter of the hairs, sebum excretion rate at the hairline, and the number of hairs shed in the 24-hour period prior to each assessment. At the end of the study, the participants were asked to complete a questionnaire regarding the cosmetic acceptability of the test shampoos.

Forty-four ketoconazole users and forty-three zinc pyrithione users completed the 6 month study period. Analysis of the different parameters shows that the hair diameter gradually increases with chronic ketoconazole use (+8.46%) over a 6 month period, whereas the diameter shows a trend to decrease with zinc pyrithione use over the same period (-2.28%). The sebum excretion rate is reduced with ketoconazole (-6.54%) while it increases with zinc pyrithione (+8.2%) over the same period of time. The number of hair shed over a 24-hour period is reduced by 16.46% with ketoconazole and 6.02% with zinc pyrithione after 6 months. Finally, the percentage hairs in anagen phase increased by 6.4% and 8.4% respectively during the study time. Except for the percentage of hairs in anagen, which showed no difference between the two groups, all other parameters were significantly different in favor of the ketoconazole shampoo.

Both shampoos have been shown to be good anti-dandruff ingredients. Assessment of parameters than can affect the health of hair and scalp, suggests that both ingredients show distinct differences in the way they affect the scalp; indicating that ketoconazole increases hair diameter and reduces scalp oil, whereas zinc pyrithione seems to yield opposite effects. This suggests that, besides their effect on the lipophilic yeast Malassezia spp, ketoconazole and zinc pyrithione act though quite different mechanisms. An overall analysis of hair diameter changes as a function of changes in sebum excretion rate suggests that a reduction in scalp oiliness seems to result in an increased hair diameter. This suggests that, in people with oily hair, regular use of ketoconazole shampoo may result in overall hair fullness.


THIRD STUDY

Home About Products & Services Contact Us

International Journal of Cosmetic Science
Current Issue Archive



October 2002, 24:5 > Nudging hair shedding by antidandruff... < Previous | Next >
ARTICLE LINKS:
Fulltext | PDF (197 K)
Nudging hair shedding by antidandruff shampoos. A comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations.

Original Articles

International Journal of Cosmetic Science. 24(5):249-256, October 2002.
Pierard-Franchimont, C.; Goffin, V.; Henry, F.; Uhoda, I.; Braham, C.; Pierard, G. E.
Abstract:
Synopsis: Hair shedding and hair thinning have been reported to be affected by dandruff and seborrhoeic dermatitis. The present study was conducted in 150 men presenting with telogen effluvium related to androgenic alopecia associated with dandruff. They were randomly allocated to three groups receiving each one of the three shampoos in the market containing either 1% ketoconazole (KTZ), 1% piroctone olamine (PTO) or 1% zinc pyrithione (ZPT). Shampoos had to be used 2-3 times a week for 6 months. Hair shedding during shampoo was evaluated semiquantitatively. Hair density on the vertex was evaluated on photographs using a Dermaphot. Trichograms were used for determining the anagen hair percentage and the mean proximal hair shaft diameter using computerized image analysis. The sebum excretion rate (SER, [mu]g cm-2 h-1) was also measured using a Sebumeter(R).

The three treatments cleared pruritus and dandruff rapidly. At end point, hair density was unchanged, although hair shedding was decreased (KTZ: -17.3%, PTO: -16.5%, ZPT: -10.1%) and the anagen hair percentage was increased (KTZ: 4.9%, PTO: 7.9%, ZPT: 6.8%). The effect on the mean hair shaft diameter was contrasted between the three groups of volunteers (KTZ: 5.4%, PTO: 7.7%, ZPT: -2.2%). In conclusion, telogen effluvium was controlled by KTZ, PTO and ZPT shampoos at 1% concentration. In addition, KTZ and PTO increased the mean hair shaft thickness while discretely decreasing the sebum output at the skin surface.

(C) 2002 Blackwell Science Ltd.





The ketoconazole study has some pictures that speak for themselves, http://www.jdsjournal.com/article/PIIS0 ... 0/fulltext



There is also a fourth ketoconazole (Nizoral study) in the library section of this website that show increased hair density, and a 19 percent decrease in sebum secretions with nizoral usage. Hair size is also increased.



Thats four shampoo studies and one cream study that all confirm nizoral is good for Androgenetic Alopecia. Keep in mind that the men using the shampoos were not told to LEAVE THE NIZORAL IN FOR SEVERAL MINUTES, which would assuredly make it more effective and close to the level of the cream's effectiveness if so applied.







On Roxythromicyn.....................I was super exicted about it years ago, until I read the pre-clinical results. Only 8 out of 11 had benefit, but of those only 4 saw enough regrowth to rate it as more than mere slight regrowth. That is about one third of users. Most people that use finasteride who aren't too old get some pretty good benefit.
My own personal advice is to use finas, nizoral, and either minoxidil or prox-n. Loren Pickart has come out with a new folligen with some anti-androgens that probably is an improvement over what he had............that might be something to look into.


Until we find exactly what the immune system attacks in Androgenetic Alopecia and what countermeasure can be taken against it, anti-androgens are the best known way to stop more of it from occuring. Roxythromicyn for example, would work much better with finasteride together as a combo undoubtably.
 

larry27

New Member
Reaction score
0
the study with impresive photos is that i mentioned in the other post. :innocent:
the other estudies are new for me, thanks for sharing.
like you i was expect more results of the roxy study, but is a new
way to probe, and sure are better sustances than roxy to fight
the apoptosis and inflamation
 

bornthisway

Established Member
Reaction score
9
Print published.

Journal Archives of Dermatological Research
Issue Volume 301, Number 5 / June, 2009

Abstract Roxithromycin (RXM) is a 14-member macrolide antibiotics, with a variety of bioregulatory functions including anti-apoptotic activity to keratinocytes. Therefore, RXM has been used for many kinds of skin diseases. In this study, human and murine hair follicles were treated with RXM in order to find the possibility to cure hair loss disease such as androgenetic alopecia (Androgenetic Alopecia). In Androgenetic Alopecia, dihydrotestosterone signals apoptosis in dermal papilla cells in susceptible individuals, resting in premature termination of anagen and early entry into catagen. Therefore, anti-apoptotitic drug has a possibility of new candidate for Androgenetic Alopecia. This study revealed RXM antagonized the in vitro inhibitory effect of IFN-? on proliferation of keratinocytes and induction of apoptosis in murine and human hair bulb. RXM increases hair elongation and inhibits catagen-like changes induced in vitro with IFN-? in murine and human hair follicles. Furthermore, topical 5% RXM solution effectively restores hair growth in about half of individuals with Androgenetic Alopecia without any local and systemic adverse effects. Therefore, RXM is new candidate as a hair restoration drug for Androgenetic Alopecia.
 
Top